Search

Your search keyword '"Almasio, Piero L."' showing total 133 results

Search Constraints

Start Over You searched for: Author "Almasio, Piero L." Remove constraint Author: "Almasio, Piero L."
133 results on '"Almasio, Piero L."'

Search Results

1. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

2. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

3. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials

4. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

10. Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581]

13. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates)

14. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

16. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

18. Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature

19. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

20. Chronic hepatitis B in Italy: new features of an old disease - approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection

31. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

35. Rivaroxaban-induced hepatotoxicity

36. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.

37. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus

38. Su1237 A Retrospective Multicenter Survey on Infliximab Efficacy and Safety in Moderate-to-Severe and Steroid-Dependent Ulcerative Colitis

41. Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature

43. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis

44. Hepatitis C transmission: current issues (Part One)

45. The long-term course of chronic hepatitis B

47. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies.

48. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus.

50. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease

Catalog

Books, media, physical & digital resources